Macrogen Inc (038290) - Total Liabilities
Based on the latest financial reports, Macrogen Inc (038290) has total liabilities worth ₩173.25 Billion KRW (≈ $117.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Macrogen Inc cash conversion from operations to assess how effectively this company generates cash.
Macrogen Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Macrogen Inc's total liabilities have evolved over time, based on quarterly financial data. Check Macrogen Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Macrogen Inc Competitors by Total Liabilities
The table below lists competitors of Macrogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crossject
PA:ALCJ
|
France | €32.49 Million |
|
Yuhwa Sec
KO:003460
|
Korea | ₩217.69 Billion |
|
Cube Entertainment Inc
KQ:182360
|
Korea | ₩97.35 Billion |
|
Nonthavej Hospital Public Company Limited
BK:NTV
|
Thailand | ฿366.81 Million |
|
Control Print Limited
NSE:CONTROLPR
|
India | Rs985.53 Million |
|
Gan Shmuel
TA:GSFI
|
Israel | ILA71.92 Million |
|
TOPMATERIAL LTD
KQ:360070
|
Korea | ₩72.50 Billion |
|
Vacasa Inc
NASDAQ:VCSA
|
USA | $468.78 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Macrogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 038290 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Macrogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Macrogen Inc (2011–2024)
The table below shows the annual total liabilities of Macrogen Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩152.23 Billion ≈ $103.17 Million |
+54.35% |
| 2023-12-31 | ₩98.63 Billion ≈ $66.84 Million |
-2.16% |
| 2022-12-31 | ₩100.80 Billion ≈ $68.31 Million |
+0.27% |
| 2021-12-31 | ₩100.53 Billion ≈ $68.13 Million |
+12.15% |
| 2020-12-31 | ₩89.64 Billion ≈ $60.75 Million |
-20.11% |
| 2019-12-31 | ₩112.20 Billion ≈ $76.04 Million |
+82.48% |
| 2018-12-31 | ₩61.49 Billion ≈ $41.67 Million |
-27.17% |
| 2017-12-31 | ₩84.43 Billion ≈ $57.22 Million |
+9.69% |
| 2016-12-31 | ₩76.97 Billion ≈ $52.16 Million |
+32.26% |
| 2015-12-31 | ₩58.20 Billion ≈ $39.44 Million |
+18.66% |
| 2014-12-31 | ₩49.05 Billion ≈ $33.24 Million |
+77.29% |
| 2013-12-31 | ₩27.66 Billion ≈ $18.75 Million |
-9.02% |
| 2012-12-31 | ₩30.41 Billion ≈ $20.61 Million |
+107.57% |
| 2011-12-31 | ₩14.65 Billion ≈ $9.93 Million |
-- |
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more